The AHA today urged the Health Resources and Services Administration to implement its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers without delay. “Delaying the implementation of the ceiling price and CMPs an additional nine months – from Oct. 1, 2017 to July 1, 2018 – is not justified given the exhaustive development process that has occurred,” wrote AHA Executive Vice President Tom Nickels. AHA also reiterated its support for HRSA’s decision to codify its “penny pricing policy” to strengthen oversight of 340B ceiling prices and discourage manufacturers from raising prices faster than inflation. “While this policy has been in place for many years, drug manufacturers have not applied it consistently,” AHA said. “…In addition, we look forward to working with HRSA on further guidance on the 340B ceiling reporting system and how 340B hospitals and covered entities can access ceiling price information to establish instances of manufacturer overcharges.”

Related News Articles

Headline
The Centers for Medicare & Medicaid Services yesterday released a fact sheet for state and local governments seeking Medicare, Medicaid or Children’s…
Headline
Over 1,750 Medicare Part D prescription drug plans and Medicare Advantage plans with prescription drug coverage have applied to offer lower insulin costs…
Headline
The Government Accountability Office today named three new members to the Medicare Payment Advisory Commission through April 2023. They are: Wayne…
Headline
More than half of U.S. adults aged 70 and older have experienced a disruption in their medical care during the first month of social distancing for COVID-19,…
Headline
The AHA and other national hospital organizations today urged the Department of Health and Human Services and Centers for Medicare & Medicaid Services to…
Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2026, according to the latest annual report from the…